Answer
Elrexfio (elranatamab)'s initial cytokine release may suppress CYP enzymes, increasing interaction risk with warfarin, a narrow-therapeutic-index CYP substrate, so toxicity or drug concentrations should be monitored during and up to 14 days after step-up dosing and cytokine release syndrome, with warfarin dose adjustment as needed.
Sources for this answer
- ELREXFIO 40 mg/mL solution for injectionPfizer Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 8Document updated
Sources checked